OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Someone has just acquired 3% OF THE CO and the shares still go down. If I sold some the sp would shoot up, so lets just say i've sold today.

OXB is really not getting places - it has been in this region of 16-19p for ages.

OXB shall be a success story of 2005-6, with licence agreements underpinning the development budget. I keep buying around 17p. I hold 120,000 stock. management are really excellent, with the best contacts in the business. They are almost above th3e biz .. like British Bio should have been , but got tainted . Prof Kingsman didn't let himself be so influenced.
You should see 30p tested by summer .If not later in the year, thanks to Trovax and other developments. if you are intersteed in increasing a sum of cash from X to X plus 50% in one year, this is such a company. If you want to do it ina fortnight, try the pools.

It's time to get back in - with the sellers out the way, and price hitting 17 again, good news to come will push this overlooked Gem up above 20 and the graph will show a golden cross meaning onwards and upwards this yr to 45p

3 companies have acquired a sizeable stake, who are the Sputnik Group? Let's hope they don't get taken over as I want these long term as they're going to be worth many pounds. Something's afoot anyway, Trovax is coming of age and will be a rael money spinner, the other technologies are so awesome, they're just too difficult to understand but the applications are endless and worth a fortune, no reason for this low price.

Another licence deal would kick start it or news of the trials, there's a lot of newsflow tocome, progress reports and possible big deals so price could take off.

Some very good buys - 500k etc so why the sudden interest?

rvitler- not sure but is it a coincidence that Cenes (CEN), who I also hold shares in, has the same upward movement???

Used to have that one yrs ago, but not quite in OXB league, I strogly believe that 05 will be OXB breakout yr and 50p +

Some suggestion from sources unknown (London broker) that OXB might be a possible target. Nothing known - and could easily be a rumour started to drum up some trading in OXB.

Oxford Biomedica PLC
19 January 2005




NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN


Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')

Response to share price movement

The Board of Oxford BioMedica notes the recent movement in the Company's share
price. The Board confirms that it has received an approach from a third party
and that it is in discussions regarding a potential merger.

The Board wishes to stress that discussions are at an early stage and may or may
not lead to an offer for the Company.

19 January 2005


Enquiries:
Oxford BioMedica plc Tel: +44 (0) 1865 783000
Professor Alan Kingsman, Chief Executive Officer
Andrew Wood, Chief Financial Officer






This information is provided by RNS
The company news service from the London Stock Exchange

Panchandl - Great so what does your crystal ball say this morning. Any views on the long term - I have never done that well with mergers but this could be an exception.

Depends on the drug pipeline of the other firm. I cannot find anything out about it so far.

Interesting that two others in my portfolio are leaping this morning MDW and CEN and SKP holding its own (I cant see its any of them but you never know) I know that I have too many biotech stocks for my health - but this mornng the medicine tastes fine.

A takeover is more likely at this price unless they merge with a small co. I really hope it's not the latter which would dilute this great co. I'd prefer it remains autonomous as one day this technolgy will be worth pounds per share and to sell out at these levels would be awful. Expect another big rise tomorrow, could hit 30p by end of week, maybe more.

What would a takeover price be for OXB?30p seems to be too low.Also,I can't see any really BIG money in on this news.Why not?

The rns refers to a merger - not a take over. Thus, it is the range of pipeline drugs that the other co brings to the deal which is so important. I accept the possibility that the mereger might involve a much larger company (such as Biogen - mooted elsewhere) but this is very unlikely because a take-over would be the more sensible option. The reverse is also true if OXB are dealing with a much smaller company. I have no information about this possible merger but I wonder whether Vernalis, or perhaps Cenes, might be involved.

Top % Gainers
# EPIC Name Price Chg %
1 DBE Dunham-bush Ord 2.5p 2.0 0.875 77.78
2 IGA Ingenta Ord 1p 4.225 0.875 26.12
3 EVS Envesta Ord 1p 2.9 0.55 23.4
4 NMT Nmt Group Ord 4 67.5 11.5 20.54
5 MCR Mercator Ord 1p 9.5 1.375 16.92
6 PMG Pc Medics Grp Ord 0.25p 0.7 0.1 16.67
7 EIC Eicom Ord 0.5p 0.55 0.075 15.79
8 AXO Axon Grp. Ord 1p 173.5 23.5 15.67
9 OXB Oxford Biomed. Ord 1p 22.25 3.0 15.58

I can't see a merger going ahead under 30p equiv, that would severeley undervalue this company. A merger once announced I think would really increase the sp for the other co. concerned as it will have to be a similar sized co. and OXB is so undervalued, it will bring so much to the enlarged co. If a much larger co., then at these prices they may aswell bid for it outright but if that is not happening, the value of the the experts in OXB is obviously too much to lose and therefore a merger is the only option. OXB should not merge but remain independent and enter license agreements/affiliations instead.

robstuff - not quite sure I understand your logic but agree that a takeover would be more likely but I also think it would be extremely beneficial to merge with another with similar expertise/complimentary products - a sharing of brains and economies of scale and more power in contracting deals. Also think we'll see 30p over the next week, as it's been recognised how undervalued this co is and the articles in the press should highlight that.